Why the study?
Very-high-power, very-short-duration radiofrequency ablation was evaluated to assess its efficiency and feasibility as an ablation strategy for symptomatic premature ventricular contractions originating from the right ventricular outflow tract.
Does very-high-power, very-short-duration (VHPSD) radiofrequency ablation eliminate premature ventricular contractions in a patient with symptomatic RVOT PVCs?
Does very-high-power, very-short-duration (VHPSD) radiofrequency ablation eliminate premature ventricular contractions in a patient with symptomatic RVOT PVCs?
Very-high-power, very-short-duration (VHPSD) radiofrequency ablation may be a highly efficient and safe first-line strategy for treating symptomatic RVOT PVCs.
This technical report presents a compelling case for the use of very-high-power, very-short-duration (VHPSD) radiofrequency ablation as a promising and efficient strategy for treating symptomatic premature ventricular contractions (PVCs) originating from the right ventricular outflow tract (RVOT). The patient with frequent, symptomatic PVCs and a 24% burden underwent successful ablation using a 90 W/4 s recipe via the QDOT MICRO™ catheter. The procedure resulted in immediate and sustained elimination of PVCs, with only 4 s of ablation time, near-zero fluoroscopy, no complications, and no PVC recurrence at 6 months. VHPSD ablation, though originally developed for atrial fibrillation, demonstrated remarkable procedural efficiency, precision, and lesion efficacy in this case. Compared to standard power, long-duration (SPLD) ablation, VHPSD offers the potential to significantly reduce procedural time, minimize tissue edema, and lower complication risk, particularly advantageous in anatomically challenging areas or in situations where maintaining stable catheter contact for extended periods is difficult or unfeasible. This technical report suggests the transformative potential of VHPSD as a first-line ablation strategy for RVOT-PVCs, provided careful mapping and appropriate technique are used. It underscores the need for further prospective studies to validate its broader safety, efficacy, and role in PVC management, particularly in cases involving intramural origins.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: